{"name":"Almirall","slug":"almirall","ticker":"ALM.MC","exchange":"Bolsa de Madrid","domain":"almirall.com","description":"Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944.","hq":"Barcelona, Spain","founded":1968,"employees":"2108","ceo":"Gianfranco Nazzi","sector":"Dermatology","stockPrice":12.42,"stockChange":0.36,"stockChangePercent":2.99,"marketCap":"$2.7B","metrics":{"revenue":1114531968,"revenueGrowth":11.4,"grossMargin":76.7,"rdSpend":0,"netIncome":46154000,"cash":338819008,"dividendYield":1.49,"peRatio":56.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1979-01-01","label":"Aczone first approved","drug":"Aczone","drugSlug":"dapsone","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Altabax first approved","drug":"Altabax","drugSlug":"retapamulin","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Klisyri first approved","drug":"Klisyri","drugSlug":"tirbanibulin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Eklira patent cliff ($1.2B at risk)","drug":"Eklira","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Tudorza patent cliff ($0.8B at risk)","drug":"Tudorza","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"LAS106521","genericName":"LAS106521","slug":"las106521","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LAS41005","genericName":"LAS41005","slug":"las41005","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LASW1510","genericName":"LASW1510","slug":"lasw1510","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LAS41007","genericName":"LAS41007","slug":"las41007","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LAS41008","genericName":"LAS41008","slug":"las41008","indication":"Psoriasis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"infectious","drugs":[{"name":"Experimental: LAS 41004 dosage 1","genericName":"Experimental: LAS 41004 dosage 1","slug":"experimental-las-41004-dosage-1","indication":"Other","status":"phase_2"},{"name":"Klisyri","genericName":"TIRBANIBULIN","slug":"tirbanibulin","indication":"Actinic keratosis","status":"marketed"},{"name":"LAD603","genericName":"LAD603","slug":"lad603","indication":"Other","status":"phase_2"},{"name":"LAS41003","genericName":"LAS41003","slug":"las41003","indication":"Other","status":"phase_2"},{"name":"Tirbanibulin ointment 1%","genericName":"Tirbanibulin ointment 1%","slug":"tirbanibulin-ointment-1","indication":"Other","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Aczone","genericName":"DAPSONE","slug":"dapsone","indication":"Acne vulgaris","status":"marketed"},{"name":"KX2-391 Ointment 1%","genericName":"KX2-391 Ointment 1%","slug":"kx2-391-ointment-1","indication":"Atopic dermatitis","status":"phase_3"},{"name":"dapsone gel","genericName":"dapsone gel","slug":"dapsone-gel","indication":"Acne vulgaris","status":"marketed"},{"name":"dapsone gel vehicle","genericName":"dapsone gel vehicle","slug":"dapsone-gel-vehicle","indication":"Acne vulgaris (topical gel formulation)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"LASW1835","genericName":"LASW1835","slug":"lasw1835","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"vehicle of LAS41007","genericName":"vehicle of LAS41007","slug":"vehicle-of-las41007","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Altabax","genericName":"RETAPAMULIN","slug":"retapamulin","indication":"Impetigo","status":"marketed"}]}],"pipeline":[{"name":"Aczone","genericName":"DAPSONE","slug":"dapsone","phase":"marketed","mechanism":"Aczone works by inhibiting bacterial growth and reducing inflammation through its sulfone properties.","indications":["Acne vulgaris","Dermatitis herpetiformis","Leprosy"],"catalyst":""},{"name":"LAS106521","genericName":"LAS106521","slug":"las106521","phase":"phase_3","mechanism":"LAS106521 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LAS41005","genericName":"LAS41005","slug":"las41005","phase":"phase_3","mechanism":"LAS41005 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LASW1510","genericName":"LASW1510","slug":"lasw1510","phase":"phase_3","mechanism":"LASW1510 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LASW1835","genericName":"LASW1835","slug":"lasw1835","phase":"phase_3","mechanism":"LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"Altabax","genericName":"RETAPAMULIN","slug":"retapamulin","phase":"marketed","mechanism":"Small molecule","indications":["Impetigo","Superficial bacterial infection of skin"],"catalyst":""},{"name":"Experimental: LAS 41004 dosage 1","genericName":"Experimental: LAS 41004 dosage 1","slug":"experimental-las-41004-dosage-1","phase":"phase_2","mechanism":"LAS 41004 is an investigational compound being developed by Almirall for dermatological or respiratory conditions, though its precise mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"KX2-391 Ointment 1%","genericName":"KX2-391 Ointment 1%","slug":"kx2-391-ointment-1","phase":"phase_3","mechanism":"KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis.","indications":["Atopic dermatitis"],"catalyst":""},{"name":"Klisyri","genericName":"TIRBANIBULIN","slug":"tirbanibulin","phase":"marketed","mechanism":"Klisyri works by disrupting the microtubule network, which is essential for cell division.","indications":["Actinic keratosis"],"catalyst":""},{"name":"LAD603","genericName":"LAD603","slug":"lad603","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LAS41003","genericName":"LAS41003","slug":"las41003","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LAS41007","genericName":"LAS41007","slug":"las41007","phase":"phase_3","mechanism":"LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LAS41008","genericName":"LAS41008","slug":"las41008","phase":"phase_3","mechanism":"LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Psoriasis","Atopic dermatitis"],"catalyst":""},{"name":"Tirbanibulin ointment 1%","genericName":"Tirbanibulin ointment 1%","slug":"tirbanibulin-ointment-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"dapsone gel","genericName":"dapsone gel","slug":"dapsone-gel","phase":"marketed","mechanism":"Small molecule","indications":["Acne vulgaris"],"catalyst":""},{"name":"dapsone gel vehicle","genericName":"dapsone gel vehicle","slug":"dapsone-gel-vehicle","phase":"phase_3","mechanism":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.","indications":["Acne vulgaris (topical gel formulation)"],"catalyst":""},{"name":"vehicle of LAS41007","genericName":"vehicle of LAS41007","slug":"vehicle-of-las41007","phase":"phase_3","mechanism":"LAS41007 is a small molecule inhibitor of the PDE4 enzyme.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Almirall Reports 2023 Full-Year Results","summary":"Almirall reported a revenue increase of 10.3% in 2023, driven by strong sales of Eklira and Tudorza.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Almirall Partners with AstraZeneca to Develop Respiratory Treatments","summary":"Almirall and AstraZeneca announced a partnership to develop new respiratory treatments, expanding Almirall's presence in the market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPSklvVUpWWGlFRGNtZy00Qy1MTVhhb1NWRDRUQXR2V0xpY1VyOUxQM0lYZWN3ME96Ti1JMnFWZnlrSVFHU0JlNXl5Mmh3dXVUc1lyYlZzMkZRM1NVRWttR2V4N3dZMk4zMDkwQkpXNDdja1JhSEszM2J2NHhLRGQxcG8wLXByN0lTRUE?oc=5","date":"2026-03-03","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Almirall (BME:ALM) Valuation After Strong Full-Year Results And Optimistic 2026 Sales Guidance - Yahoo Finance","headline":"Assessing Almirall (BME:ALM) Valuation After Strong Full-Year Results And Optimistic 2026 Sales Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQTXg5WHhEaGJ0MnBSVkwyVWFGU1FKcDg4WkdGU3JwQkU3SEdQbVZzdEdLRmkzbGlpOS1lTUhCd0ZfM3YwbjZIYXJtejZBVEp4dEptdDdOQUtjNWJCelBSUnBHOGhSZ2N3ek9QOFpOZDdpaFBHWVBtRHBTNHQzdnpKOG8yVXlhZ3pOV3hvUms5OFlWbUpMV05Ra293aUs1S0ROOHc?oc=5","date":"2020-01-10","type":"deal","source":"The Pharma Letter","summary":"$1.1 billion deal gives Lilly novel dermatitis candidate - The Pharma Letter","headline":"$1.1 billion deal gives Lilly novel dermatitis candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQa3FZUFZHc1BtWUFXUzlpUzhIWGpwNlVncWFWaFZCMXh1Um5CNGhzVENlT0hUc3N6alFVZTZZODQtU0dHcF9UMkxfUjJBa2t3Mk56UEk5SV9sTlNJUEhKdWIyblgxejdwZTUyRG80MmpKZ1RNZVMzMjFNNm1tRFJnZXd6VGsxLWQ1bmFEM3NmWE1zSWhCR3c5VFROZFdBb3lrYmpmRktVV1Y?oc=5","date":"2017-12-12","type":"deal","source":"The Pharma Letter","summary":"Almirall partners with US firm on actinic keratosis candidate - The Pharma Letter","headline":"Almirall partners with US firm on actinic keratosis candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQRG80LU5oS1FjNDR1U3BMWDBxWS1kUXViVjBjeVJmTkdkcEhBdTBuV1FZMkhUZ0pDeUEzRTV5V1Y2bWtqUlp4SGJZRkRxTk1vLTlwekhMcjc0UGN0cDFtUzVWTzlxUkl3enR4NFpwMUx6dVNwUllnaU1vZ3U2V1ZkZmd0SnNBdjVwYjJTNzZUOVJKMjVLNng0eGc2VlgyNWdkMmtzRGtJMC1hU00w?oc=5","date":"2017-07-18","type":"pipeline","source":"The Pharma Letter","summary":"Almirall looks to nanotechnology to improve dermatology products - The Pharma Letter","headline":"Almirall looks to nanotechnology to improve dermatology products","sentiment":"neutral"}],"patents":[{"drugName":"Eklira","drugSlug":"aclidinium-bromide","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Tudorza","drugSlug":"aclidinium-bromide","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"EU","annualRevenue":800000000}],"drugCount":17,"phaseCounts":{"marketed":5,"phase_3":9,"phase_2":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","GSK","Novartis"],"therapeuticFocus":["Respiratory","Skin Diseases"],"financials":null,"yahoo":{"currentPrice":12.42,"previousClose":12.06,"fiftyTwoWeekHigh":13.98,"fiftyTwoWeekLow":8.67,"fiftyTwoWeekRange":"8.67 - 13.98","fiftyDayAverage":12.46,"twoHundredDayAverage":11.97,"beta":0.19,"enterpriseValue":2598005504,"forwardPE":22.3,"priceToBook":1.79,"priceToSales":2.39,"enterpriseToRevenue":2.33,"enterpriseToEbitda":12.79,"pegRatio":0,"ebitda":203204992,"ebitdaMargin":18.2,"freeCashflow":34954248,"operatingCashflow":174459008,"totalDebt":346515008,"debtToEquity":23.3,"currentRatio":2.04,"returnOnAssets":1.9,"returnOnEquity":3.1,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":14.41,"targetHighPrice":16,"targetLowPrice":12.5,"dividendRate":0.18,"payoutRatio":0.84,"fiveYearAvgDividendYield":1.83,"exDividendDate":1747267200,"insiderHeldPercent":65,"institutionHeldPercent":18.1,"sharesOutstanding":214630834,"floatShares":75350943,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.22,"epsForward":0.56,"revenuePerShare":5.21,"bookValue":6.92,"officers":[{"age":53,"name":"Mr. Carlos  Gallardo Piqué","title":"CEO, President, Member of Management Board & Chairman of the Board"},{"age":52,"name":"Mr. Jon U. Garay Alonso","title":"CFO & Member of Management Board"},{"age":null,"name":"Mr. Eloi  Crespo Cervera","title":"Chief Industrial Operations Officer & Member of Management Board"},{"age":null,"name":"Mr. Esteve  Conesa Panicot","title":"Chief People & Culture Officer and Member of Management Board"},{"age":null,"name":"Dr. Volker  Koscielny","title":"Chief Medical Officer & Member of Management Board"},{"age":null,"name":"Dr. Karl  Ziegelbauer","title":"Chief Scientific Officer & Member of Management Board"},{"age":null,"name":"Ms. Isabel Cristina Gomes","title":"Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board"},{"age":null,"name":"Mr. Paul  Rittman","title":"Member of Management Board and President & GM of Almirall US"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://investors.almirall.es/phoenix.zhtml?c=209345&p=irol-irhome","website":"https://www.almirall.com","phone":"34 93 291 30 00"}}